Open AccessEfficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study
Author(s) -
Bin Su,
Yifei Cheng,
Quan Zhao,
Weiping Cai,
Min Wang,
Hongzhou Lu,
Yuanyuan Chen,
Li Liu,
Hui Wang,
Yun He,
Yuhua Zheng,
Linghua Li,
Jinfeng Chen,
Jianhua Yu,
Bin Zhu,
Min Zhao,
Yongtao Sun,
Wenhui Lun,
Wei Xia,
Lijun Sun,
Lili Dai,
Taiyi Jiang,
Meixia Wang,
Qingshan Zheng,
Haiyan Peng,
Yao Wang,
Rui Lü,
Jianhua Hu,
Hui Xing,
Yiming Shao,
Dong Xie,
Tong Zhang,
Fujie Zhang,
Hao Wu
Publication year - 2020
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001273
Subject(s) - lopinavir , medicine , ritonavir , adverse effect , interim analysis , viral load , randomized controlled trial , clinical endpoint , population , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , environmental health
Albuvirtide is a once-weekly injectable human immunodeficiency virus (HIV)-1 fusion inhibitor. We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.